Daxor reports net assets were $30,359,013 or $6.33 p/s as of June 30

As of June 30 Daxor’s net assets were $30,359,013 or $6.33 per share as compared to $28,969,469, or $6.75 per share on December 31, 2022. This increase in net assets is primarily due to the public offering during the six-month period ended June 30 , whereby Daxor raised $4.1M net to Daxor by selling 464,599 shares at $9.75. The net asset value per share was adjusted to account for the addition of 464,599 shares to the float of the stock. For the six-month period ended June 30 Daxor had net dividend income of $77,990, and net realized gains on investment activity of $603,661. Focusing further on the operating division financial performance, the Company is pleased to report a 20.64% increase in the unaudited revenues of our single-use test kits for the six-month period ended June 30, as compared to the six-month period ended June 30, 2022. Revenue growth was driven by a combination of the sale and leasing of our capital equipment to hospitals and orders for our single-use blood volume diagnostics kits for heart failure management, critical care use, among other indications… In June of this year Daxor launched its new ezBVA Lab service for clinical sites that wish to perform BVA testing using Daxor’s lab services without the need for an on-site analyzer. This new service, priced at $965 per test, represents a significant value for customers and is a premium to the sale of a test kit which sells for $385.